Clinical trials: B-Non Hodgkin Lymphoma
Lymphoma, Non-Hodgkin
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.
- Trial name
- NCT04638270
- Testing
- anti-CD19 FasT CAR-T cells
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Central Nervous System Lymphoma
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
- Trial name
- NCT03684980
- Testing
- Methotrexate, Rituximab, leucovorin
- Where
- 11 sites in United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
B-cell Non-Hodgkin's Lymphoma
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.
- Trial name
- NCT06314828
- Testing
- RJMty19 (CD19-CAR-DNT cells)
- Volunteers
- 30 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Non-Hodgkin Lymphomas
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT01078922
- Testing
- Ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Oncology Specialists, S.C.
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line therapy for…
- Trial name
- ZR2-CHOP (NCT05200312)
- Testing
- Zanubrutinib, Lenalidomide, Rituximab
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by…
- Conditions
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03217253
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma
Co-administration of CART22-65s and huCART19 for B-ALL
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT05674175
- Testing
- Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s), Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Stephan Grupp MD PhD
Leukemia, B-cell, Lymphoma, B-Cell
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04648475
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Diffuse Large B-cell Lymphoma
Erythropoietin for Management of Anemia Caused by Chemotherapy
This is a phase Ⅱ study of erythropoietin for management of anemia caused by chemotherapy in patients with Diffuse Large B-cell Lymphoma.
- Trial name
- NCT02890602
- Testing
- Darbepoetin alfa, R-CHOP
- Volunteers
- 53 people
- Sponsor
- Kosin University Gospel Hospital
B-Cell Lymphoma
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
- Trial name
- NCT02395601
- Testing
- CPI-1205
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Constellation Pharmaceuticals
Non-Hodgkin Lymphoma Refractory/ Relapsed
Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
- Trial name
- NCT06334991
- Testing
- CD19 t-haNK
- Where
- 3 sites in South Africa
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
Diffuse Large B Cell Lymphoma
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Subjects (patients), will receive single infusions of pembrolizumab in combination with CXD101 every 3 weeks for two years or until disease progression or unacceptable toxicity develops.
- Trial name
- PLACARD (NCT03873025)
- Testing
- Pembrolizumab and CXD101
- Sponsor
- University College, London
B-cell Lymphoma
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
This Phase 1, open-label, single-arm, dose-escalation study is designed to evaluate the safety and tolerability of SL1617 Injection in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07775508
- Testing
- SL1617 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chinese PLA General Hospital
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL).
- Trial name
- EPCORE™ NHL-2 (NCT04663347)
- Testing
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Genmab
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma.
- Trial name
- NCT06445517
- Testing
- ISM8207
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06393335
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.